Akebia Therapeutics Inc. Stock
Price
Target price
?
?
2.110%
0.028
2.110%
€6.16
07:34 / Stuttgart Stock Exchange
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akebia Therapeutics Inc. Stock
There is an upward development for Akebia Therapeutics Inc. compared to yesterday, with an increase of €0.028 (2.110%).
With 12 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 6 € there is potential for a 343.46% increase which would mean more than doubling the current price of 1.35 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | 2.110% | 2.396% | -23.851% | -28.456% | -27.635% | 368.198% | -44.328% |
| Ardelyx Inc. | 0.040% | 2.185% | 3.441% | 0.960% | 1.712% | 197.935% | -3.034% |
| Krystal Biotech | 0.050% | 10.715% | 18.830% | 17.200% | 34.757% | 188.873% | - |
| Evolus Inc | 0.860% | 3.571% | -4.132% | -48.673% | -44.762% | -17.143% | 95.616% |
Comments
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia (AKBA) Q2 Revenue Jumps 43%
Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news
